Table 4 Pharmacokinetic parameters of LXT-101 sustained-release suspension after administration (Mean ± SD).

From: Development and validation of an LC–MS/MS method for quantitative determination of LXT-101 sustained-release suspension, a novel drug in treating prostate cancer, in beagle plasma

Parameters

Dose (mg/kg)

20 (single-dose, n = 3)

40 (single-dose, n = 6)

40 (repeated-dose, n = 3)

AUC0-t (ng/mL·d)

588.09 ± 137.79

1203.62 ± 877.42

2825.71 ± 628.24

AUC0-∞ (ng/mL·d)

592.89 ± 134.21

1209.97 ± 873.78

2848.15 ± 611.33

MRT (d)

5.72 ± 1.34

5.61 ± 1.73

13.60 ± 0.12

T1/2Z (d)

1.61 ± 0.73

3.26 ± 2.27

4.56 ± 2.09

Tmax (d)

0.08 ± 0.00

0.08 ± 0.00

12.33 ± 0.58

Cmax (ng/mL)

166.85 ± 20.90

802.13 ± 589.47

568.61 ± 51.13

Vz/F (L)

85.53 ± 51.81

264.29 ± 270.61

97.96 ± 60.39

Clz/F (L/d)

34.81 ± 7.13

45.62 ± 24.30

14.45 ± 2.88

Back to article page